Acne Scars - AtrophicNCT07906509
Comparative Study of The Efficacy and Safety of Subcision Combined With Injection of Exosomes Versus Subcision Alone in Treatment of Atrophic Post- Acne Scars.
A study testing Subcision plus exosome injection and Subcision in people with Acne Scars - Atrophic, run by Tanta University at 1 site in Egypt.
Trial summary
This split-face comparative prospective study was carried out on 20 patients presenting with atrophic post-acne scars. All participants were subjected to full history taking, general and dermatological examination, photographing before, during and after the end of the treatment. Read more about this study
- Who is it for?
- Ages 18 to 50 years
- Conditions the study is for
- Acne Scars - Atrophic
- What is being tested?
- Subcision plus exosome injection and Subcision
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteEgypt
- Study dates
- 15 May 2024to 12 Feb 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- patients with atrophic acne scars with bilateral and nearly symmetrical presentation who agree to be enrolled in the study
Who cannot join
- active acne History of keloids Bleeding and coagulation disorders
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Comparative Study of The Efficacy and Safety of Combined Subcision With Exosomes Injection Versus Subcision Alone in Treatment of Atrophic Post- Acne Scars
This split-face comparative prospective study was carried out on 20 patients presenting with atrophic post-acne scars. All participants were subjected to full history taking, general and dermatological examination, photographing before, during and after the end of the treatment. On the right side, combined subcision with exosomes injection was performed, whereas subcision alone was performed on the left side. Three treatment sessions were administered at 4-week intervals, followed by monthly follow-up for 3 months.
Before the treatment sessions, patients were instructed to put topical anesthetic cream. During sessions, the treated areas were disinfected by alcohol 70%,1 ml of lidocaine Hcl 2% was administered into the treatment site at the subdermal level, subcision was done on both sides followed by 1 ml of intralesional exosome injection on the right side only. After sessions, patients were advised to put topical antibiotic twice daily for one week. In addition, patients advised to take systemic antibiotic therapy twice daily for one week.
- Conditions
- Acne Scars - Atrophic
- Being tested
- Subcision plus exosome injection, Subcision
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Subcision plus exosome injectionProcedure or surgery
Three treatment sessions at monthly interval
SubcisionProcedure or surgery
Three treatment sessions at monthly interval
| Study group | Role | What they receive |
|---|---|---|
| Subcision followed by exosome injection | Active comparator | S Receives: Procedure: Subcision plus exosome injection |
| Subcision alone | Active comparator | Not described Receives: Procedure: Subcision |
What is being measured
The primary outcome is the main question the study is designed to answer.
Quartile grading scale
Two blinded dermatologists will compare the photos of patients before and after treatment
Measured: After 3 months from the last treatment session
Secondary outcomes (2)
Goodman and Baron scale
Measured: Before and after 3 months from the last treatment session
Ultrasonic evaluation of skin thickness
Measured: Before and after 3 months of treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Oct 2026
- Study start15 May 2024
- Primary completion12 Dec 2025
- Study completion12 Feb 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acne Scars - AtrophicStudies of the same condition, open and under way.
- More trials run by Tanta UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Model description
- Split-face ( right- left) comparative study
- Masking
- None (open label)
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- Tanta University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Aya Ashraf Fouda, Tanta University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07906509
- Sponsor's protocol ID
- 36264MS531/3/24
- Other IDs
- PACTR pending
- Status last verified
- Oct 2026
- First submitted
- 24 Oct 2026
- Last updated
- 30 Oct 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparative Study of The Efficacy and Safety of Combined Subcision With Exosomes Injection Versus Subcision Alone in Treatment of Atrophic Post- Acne Scars
- ClinicalTrials.gov ID
- NCT07906509
- Acronym / sponsor ID
- 36264MS531/3/24
- Conditions
- Acne Scars - Atrophic
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- Tanta UniversityUniversity, hospital or other
- Study start
- 15 May 2024 (actual)
- Primary completion
- 12 Dec 2025 (actual)
- Study completion
- 12 Feb 2026 (actual)
- First posted
- 30 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This split-face comparative prospective study was carried out on 20 patients presenting with atrophic post-acne scars. All participants were subjected to full history taking, general and dermatological examination, photographing before, during and after the end of the treatment. On the right side, combined subcision with exosomes injection was performed, whereas subcision alone was performed on the left side. Three treatment sessions were administered at 4-week intervals, followed by monthly follow-up for 3 months.
Before the treatment sessions, patients were instructed to put topical anesthetic cream. During sessions, the treated areas were disinfected by alcohol 70%,1 ml of lidocaine Hcl 2% was administered into the treatment site at the subdermal level, subcision was done on both sides followed by 1 ml of intralesional exosome injection on the right side only. After sessions, patients were advised to put topical antibiotic twice daily for one week. In addition, patients advised to take systemic antibiotic therapy twice daily for one week.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Split-face ( right- left) comparative study
| Arm | Type | Receives |
|---|---|---|
| Subcision followed by exosome injection | Active comparator | Procedure: Subcision plus exosome injectionS |
| Subcision alone | Active comparator | Procedure: Subcision |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- patients with atrophic acne scars with bilateral and nearly symmetrical presentation who agree to be enrolled in the study
Key exclusion criteria (1 listed)
- active acne History of keloids Bleeding and coagulation disorders
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Subcision plus exosome injectionThree treatment sessions at monthly interval | Procedure or surgery | Subcision followed by exosome injection |
| SubcisionThree treatment sessions at monthly interval | Procedure or surgery | Subcision alone |
Primary outcome
Quartile grading scale
Time frame: After 3 months from the last treatment session
Two blinded dermatologists will compare the photos of patients before and after treatment
2 secondary outcomes
Goodman and Baron scale
Time frame: Before and after 3 months from the last treatment session
Ultrasonic evaluation of skin thickness
Time frame: Before and after 3 months of treatment
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Acne Scars - Atrophic
Recruiting
Evaluation of Juläine (TM) for the Treatment of Atrophic Facial Acne Scars
Acne Scars
Recruiting
Efficacy and Tolerability of a Hybrid Fractional Laser for the Treatment of Acne Scars in Patients With Skin of Color
Acne Scars - Mixed Atrophic and Hypertrophic, Hyperpigmentation
Recruiting
Poly-L-Lactic Acid in Atrophic Acne Scars
Atrophic Acne Scarring
Recruiting
AVAVA MIRIA General Use
Acne, Acne Scars - Mixed Atrophic and Hypertrophic
Not yet recruiting
Safety and Efficacy Evaluation of the Radiofrequency Therapeutic Device for the Treatment of Atrophic Acne Scars
Acne Scars, Acne Scars - Atrophic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Subcision plus exosome injection and Subcision in people with Acne Scars - Atrophic, run by Tanta University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Quartile grading scale (time frame: After 3 months from the last treatment session). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Oct 2026.